Capital Research Global Investors Nu Cana PLC Transaction History

Capital Research Global Investors

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$2.7 - $5.04 $12.4 Million - $23.1 Million	-4,581,164 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$4.57 - $6.48 $6.23 Million - $8.83 Million	1,362,644 Added 42.34%	4,581,164 $23.7 Million
Q3 2019 Nov 14, 2019	BUY	$6.95 - $10.71 $334,767 - $515,879	48,168 Added 1.52%	3,218,520 $23.3 Million
Q2 2018 Aug 14, 2018	BUY	$19.0 - $29.84 $26.7 Million - $41.9 Million	1,403,458 Added 79.43%	3,170,352 $60.2 Million
Q1 2018 May 15, 2018	BUY	$10.04 - $28.25 $2.49 Million - $7 Million	247,646 Added 16.3%	1,766,894 $33.4 Million
Q4 2017 Feb 14, 2018	BUY	$10.0 - $18.72 $1.86 Million - $3.48 Million	185,850 Added 13.94%	1,519,248 $15.4 Million
Q3 2017 Nov 14, 2017	BUY	$16.15 - $18.37 $21.5 Million - $24.5 Million	1,333,398	1,333,398 $24.5 Million

3.33M

Ticker NCNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,196,000
Market Cap $66.3M
Description
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients ...

Get notified when there are updates to the investment portfolio of Capital Research Global Investors, based on Form 13F filings with the SEC.

Stay updated on Capital Research Global Investors with notifications on news.